Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors

Clinical Cancer Research

Volumn 13, Issue 15, 2007, Pages 4495-4502

  Siegel Lakhai, Wandena S ^a   Beijnen, Jos H ^a,c   Vervenne, Walter L ^b   Boot, Henk ^a   Keessen, Marianne ^a   Versola, Melissa ^d   Koch, Kevin M ^d   Smith, Deborah A ^d   Pandite, Lini ^d   Richel, Dirk J ^b   Schellens, Jan H M ^a,c  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYTOCHROME P450 3A4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; LAPATINIB; LOPERAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXALIPLATIN; PACLITAXEL; SOMATOMEDIN RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB;

ADD ON THERAPY; ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG CROSS REACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; MALAISE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REPEATED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES;

EID: 34547684260     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0004     Document Type: Article

References (23)

1. Slamon D, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
2. Bacus SS, Zelnich CR, Plowman G, et al. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancer: implication for tumor biology and clinical behavior. Am J Clin Pathol 1994;102:S13-24.
3. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-55.
4. Sainsbury JRC, Malcolm AJ, Appleton DR, et al. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 1985;38:1225-8.
5. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7:2-8.
6. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
7. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
8. Burris HA, Hurwitz HI, Dees C, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastaticc arcinomas. J Clin Oncol 2005;23:5305-13.
9. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparingmonthly lowdose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French intergroup study. J Clin Oncol 1997;15:808-15.
10. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil, with or without oxaliplatin, as first-line treatment in advance colorectal cancer. J Clin Oncol 2000;18:2938-47.
11. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-69.
12. Goldberg RM, Roscoe FM, Sargent DJ, et al. Mortality associated with daily bolus 5-fluorouracil/ leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer 2004;101:2170-6.
13. Schwartz G, Chu QS, Hammond LA, et al. A phase I, open-label, pharmacokinetic study of the safety and tolerability of GW572016 daily in combination with capecitabine on a three week schedule in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol 2004;23:3070.
14. Jones SF, Hainsworth JD, Spigel DR, et al. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel [abstract]. Proc Am Soc Clin Oncol 2004;23:2083.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
16. CancerTherapy Evaluation Program. Common Toxicity Criteria, version 2.0. Bethesda (MD): National Cancer Institute; 1998.
17. Hsieh S, Tobien T, Koch K, et al. Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 2004;18:285-92.
18. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-9.
19. Crone SA, Zhao Y, Fan L. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65.
20. Perez EA, Byrne JA. Results of an analysis of cardiac function in 3127 patients treated with lapatinib [abstract 583]. Proc Am Soc Clin Oncol 2006;24:18S.
21. Joel SP, Papamichael D, Richards F, et al. Lack of pharmacokinetic interaction between 5-FU and oxaliplatin. Clin Pharmacol Ther 2004;76:45-54.
22. Mosconi S, Cascinu S, Zaniboni A, et al. The value of oxaliplatin in combination with continuous infusion +/- bolus 5-FU and levo-folinic acid in metastatic colorectal cancer progressing after 5-FU based chemotherapy: a GISCAD (Italian Group for the study of digestive tract) cancer phase II trial. Tumori 2000;86:465-9.
23. Spector NL, Xia W, Burris H, et al. Study of the biological effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:1-11.